

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LUPIN LTD., LUPIN PHARMACEUTICALS INC., INNOPHARMA
LICENSING, INC., INNOPHARMA LICENSING LLC, INNOPHARMA
INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS INC., and
MYLAN INC.,

Petitioners,

v.

SENJU PHARMACEUTICAL CO., LTD.,

Patent Owner.

Case IPR2015-01105¹
Patent 8,871,813 B2

Before FRANCISCO C. PRATS, ERICA A. FRANKLIN, and
GRACE KARAFFA OBERMANN, *Administrative Patent Judges*.

FRANKLIN, *Administrative Patent Judge*.

FINAL WRITTEN DECISION
35 U.S.C. § 318(a) and 37 C.F.R. § 42.73

¹ IPR2016-00090 has been joined with this proceeding.

I. INTRODUCTION

Lupin Ltd. and Lupin Pharmaceuticals Inc. (collectively, “Lupin”) filed a Petition requesting an *inter partes* review of claims 1–27 of U.S. Patent No. 8,871,813 B2 (Ex. 1003, “the ’813 patent”). Paper 1 (“Petition” or “Pet.”). Senju Pharmaceutical Co., Ltd. (“Patent Owner”) filed a Preliminary Response to the Petition. Paper 8 (“Prelim. Resp.”).

On October 27, 2015, we instituted an *inter partes* review of claims 1–27 of the ’813 patent. Paper 9 (“Dec. Inst.”). Patent Owner filed a Patent Owner Response to the Petition. Paper 23 (Board Only), Paper 24 (Parties and Board Only), Paper 25 (Public), (collectively, “PO Resp.”).

On February 25, 2016, we instituted an *inter partes* review in IPR2016-00090 and granted the motion for joinder with IPR2015-01105, adding InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., InnoPharma LLC, Mylan Pharmaceuticals, and Mylan Inc. to the Lupin petitioner (collectively “Petitioners”). Paper 22. Petitioners filed a Reply to the Patent Owner Response. Paper 35 (Public), Paper 37 (Parties and Board Only), (collectively, “Reply”).

Both parties filed a Motion to Exclude Evidence. Paper 44 (“Pet. Mot.”) and Paper 46 (“PO Mot.”). Each party filed an Opposition to the other party’s Motion to Exclude Evidence. Paper 49 (“PO Opp.”); Paper 51 (“Pet. Opp.”). Each party filed also a Reply to the other party’s Opposition to the Motion to Exclude Evidence. Paper 55 (“Pet. Reply Opp.”); Paper 56 (“PO Reply Opp.”).

Patent Owner filed a Motion for Observation Regarding Cross Examination of Reply Witnesses, Paper 47, and Petitioners filed a Response to that motion, Paper 52.

On June 9, 2016, the parties presented arguments at an oral hearing. The hearing transcript has been entered in the record. Paper 63 (“Tr.”).

The Board has jurisdiction under 35 U.S.C. § 6(b). In this Final Written Decision, issued pursuant to 35 U.S. C. § 318(a) and 37 C.F.R. § 42.73, Petitioners have not proved by a preponderance of the evidence that claims 1–27 of the ’813 patent are unpatentable.

Petitioners’ Motion to Exclude Evidence is *dismissed* as moot. Patent Owner’s Motion to Exclude Evidence is *denied-in-part* and *dismissed-in-part* as moot.

A. *Related Proceedings*

Petitioners and Patent Owner identify a number of related district court proceedings involving the ’813 patent, including one that involves both parties in this proceeding: *Senju Pharmaceutical Co., Ltd., et al. v. Lupin, Ltd. et al.*, C.A. No. 1:15-cv-00335-JBS-KMW (D.N.J). Pet. 2; Paper 5, 3.

The parties identify also two related *inter partes* proceedings. Pet. 3; Paper 5, 3. An *inter partes* review of claims of U.S. Patent No. 8,669,290 B2 (“the ’290 patent”) was instituted in *Metrics, Inc. v. Senju Pharmaceutical Co., Ltd.*, IPR2014-01043 (trial terminated after settlement, IPR2014-01043, Paper 39) and in *InnoPharma Licensing Inc. v. Senju Pharmaceutical Co., Ltd.*, IPR2015-00902 (claims 1–30 of the ’290 patent were held not to have been shown to be unpatentable in a Final Written Decision, IPR2015-00902, Paper 90). The ’813 patent claims priority to the ’290 patent. An *inter partes* review of claims of U.S. Patent No. 8,129,431 was instituted in *Metrics, Inc. v. Senju Pharmaceutical Co., Ltd.*, IPR2014-01041 (trial terminated after settlement, IPR2014-01041, Paper 39) and in *InnoPharma Licensing Inc. v. Senju Pharmaceutical Co., Ltd.*,

IPR2015-01105
Patent 8,871,813 B2

IPR2015-00903 (claims 1–22 of the '431 patent were held not to have been shown to be unpatentable in a Final Written Decision, IPR2015-00903, Paper 83).

Additionally, an *inter partes* review was instituted for claims of U.S. Patent 8,754,131 (IPR2015-01097), U.S. Patent 8,669,290 (IPR2015-01099), and Final Written Decisions have been entered determining that the challenged claims of those patents have not been shown to be unpatentable. Also, an *inter partes* review was instituted for claims 1–30 of U.S. Patent 8,927,606 (IPR2015-01100) and a Final Written Decision in that case is entered concurrently herewith determining that the challenged claims have not been shown to be unpatentable.

B. The '813 Patent (Ex. 1003)

The '813 patent relates to a stable aqueous liquid ophthalmic preparation comprising: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid, or a pharmacologically acceptable salt or a hydrate thereof, also known by its generic name, “bromfenac”; and (b) tyloxapol. Ex. 1003, 1:7–31, 2:26–28.

The Specification explains that, prior to the invention, bromfenac was known as a non-steroidal anti-inflammatory agent (“NSAID”) effective against inflammatory diseases of the anterior and posterior segments of the eye, such as blepharitis, conjunctivitis, scleritis, and postoperative inflammation. *Id.* at 1:33–38. According to the Specification, the inventors of the '813 patent found that by adding an alkyl aryl polyether alcohol type polymer, such as tyloxapol, which is a non-ionic surfactant, to an aqueous liquid preparation of bromfenac, the preparation “becomes stable within a pH range giving no irritation to eyes, and change of the [bromfenac] . . . over

time can be inhibited, and furthermore, when the aqueous solution contains a preservative, deterioration in the preservative effect of said preservative can be inhibited for a long period of time.” *Id.* at 2:24–37, 4:13–15.

Experimental Example 1 of the ’813 patent compares the stability of bromfenac-containing ophthalmic solutions comprising 0.15 w/v% tyloxapol, 0.02 w/v% tyloxapol, 0.15 w/v% polysorbate 80, or 0.15 w/v% polyoxyl 40 stearate. *See id.* at 6:44–7:5. The stability of each preparation was tested under conditions of pH 7.0 at 60° C for 4 weeks. *Id.* at 6:62–64. The results of the comparison are shown in Table 1, reproduced below:

TABLE 1

Component	Comparison			
	Example 1	A-01	A-02	A-03
Sodium 2-amino-3-(4-bromobenzoyl)-phenylacetate	0.1 g	0.1 g	0.1 g	0.1 g
Boric acid	1.5 g	1.5 g	1.5 g	1.5 g
Benzalkonium chloride	0.005 g	0.005 g	0.005 g	0.005 g
Polysorbate 80	0.15 g	—	—	—
Polyoxyl 40 stearate	—	0.15 g	—	—
Tyloxapol	—	—	0.15 g	0.02 g
Sterile purified water	q.s.	q.s.	q.s.	q.s.
Total volume	100 mL	100 mL	100 mL	100 mL
pH	7.0	7.0	7.0	7.0
Remaining rate (%) at 60° C. after 4 weeks	51.3	63.7	73.8	89.6

Id. at 6:43–60, Table 1. As seen in Table 1, the bromfenac activity remaining in each of the tyloxapol-containing preparations (73.8% for the 0.15 w/v% tyloxapol-containing preparation and 89.6% for the 0.02 w/v% tyloxapol-containing preparation) was greater than the remaining activity in either the polysorbate 80-containing preparation (51.3%) or the polyoxyl 40 stearate-containing preparation (63.7%). *Id.*

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.